Onvansertib for relapsed small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial studies onvansertib, a targeted medicine, in people whose small cell lung cancer has come back or did not respond to prior platinum chemotherapy. It aims to shrink tumors and improve outcomes after standard treatment has already been tried.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed small cell lung cancer from pathology (biopsy) or cancer cells from testing
- Your cancer must have at least one measurable tumor spot (it must be large enough to track on scans)
- You have already tried standard platinum chemotherapy and it either failed or you couldn’t tolerate it (and you’ve had no more than two prior chemotherapy lines for widespread disease)
- You’re an adult (18 or older) and you can take oral medicine without trouble
- Your overall health must be good enough for study treatment (ECOG performance status 2 or less) and your blood/organ tests must be within required limits
- You can follow study steps, including signing consent, and women able to get pregnant and men must use effective birth control
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of drugs as a maintenance therapy after initial chemotherapy for extensive-stage small cell lung cancer. It aims to see if this combination can help keep the cancer from growing.
This trial tests a new drug, NMS-03305293, in adults with small cell lung cancer that has come back after earlier treatments. The goal is to see if it can help shrink or slow the cancer.
This study tests a combination of two chemotherapy drugs (irinotecan liposome and a platinum drug) plus an immunotherapy drug and a targeted therapy (anlotinib) as maintenance treatment after initial chemotherapy for extensive-stage small cell lung cancer. The goal is to see if this combination keeps the cancer from growing for as long as possible.
This trial tests a new drug called ABBV-706 against standard treatments (topotecan, lurbinectedin, or amrubicin) for people with small cell lung cancer that has come back or stopped responding to previous therapies. The goal is to see if ABBV-706 works better at controlling the cancer.
This trial tests a new combination of two immunotherapy drugs plus chemotherapy as the first treatment for extensive-stage small cell lung cancer. It aims to see if this combination is safe and works better than standard care.
This trial tests a new combination of immunotherapy (adebrelimab) with chemotherapy and radiation as the first treatment for extensive-stage small-cell lung cancer. It aims to see if this approach can help control the cancer better than standard treatments.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.